Superworth

PTC Therapeutics price to free cash flow PTCT

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
7.7×
May 2026
8-year median
8.0×
8-year range
5.1× to 425×
Peer median
46.0×

PTC Therapeutics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in May 2026, at 7.7×.

On the days it had one over the last 8 years, its median was 8.0×, from 5.1× in May 2025 to 425× in Jan 2019.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far7.7×7.4×8.8×
20258.9×5.1×9.8×
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
2022n/m a value too high to mean anything
2021n/m a value too high to mean anything
2020n/m a value too high to mean anything
2019390×349×425×
2018379×358×421×

Against its peers

Companies in Drug Manufacturers - General nearest PTC Therapeutics' size, closest first, today.

CompanyPrice to free cash flow
PTCTPTC Therapeuticsn/m
KNSAKiniksa Pharmaceuticals International32.7×
LGNDLigand Pharmaceuticals46.0×
INDVIndivior Pharmaceuticalsn/m
AMRXAmneal Pharmaceuticals50.9×
ARQTArcutis Biotherapeutics100×
LQDALiquidia25.3×
OGNOrganon6.4×
ALKSAlkermes plc.33.0×
TGTXTG Therapeutics477×
PTGXProtagonist Therapeutics68.6×
Peer median46.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on PTC Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.